GlassScriptPhysician profile
Asan M Ariff
NPI 1437102845
$5,225.55
in general payments reported to CMS, 2019-2025
30 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $393 · 2021: $655 · 2022: $623 · 2023: $704 · 2024: $818 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,826 · Education: $84.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,825.79 |
| Education | $84.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $808.49 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $450.56 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $322.73 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $321.58 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $318.47 | 2021-2025 | |
| Amgen INC. | $304.26 | 2019-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $282.51 | 2021-2024 | Benlysta |
| Opko Pharmaceuticals, LLC | $258.55 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $233.52 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.75 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $175.95 | 2019-2023 | Ultomiris |
| Horizon Therapeutics Plc | $173.25 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $156.43 | 2019-2023 | Eliquis |
| Akebia Therapeutics INC | $149.42 | 2019-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $135.78 | 2022-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $129.91 | 2022-2025 | Ozempic, Rybelsus |
| Vantive US Healthcare LLC | $128.34 | 2025 | |
| Baxter Healthcare | $123.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $116.05 | 2024-2025 | |
| Lilly USA, LLC | $113.91 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $78.87 | 2021-2022 | |
| Ardelyx, INC. | $61.19 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $34.83 | 2019-2023 | Injectafer |
| Scpharmaceuticals INC. | $26.07 | 2025 | |
| Abbott Laboratories | $24.49 | 2019 | |
| Cormedix INC. | $20.94 | 2025 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $19.84 | 2022 | |
| Boston Scientific Corporation | $18.11 | 2023 | |
| Apellis Pharmaceuticals, INC. | $16.92 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asan Ariff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.